Integra LifeSciences Holdings Corporation — Q3 2020 Form 10-Q
Business context and reporting period
Integra is a global medical technology company operating through two segments: Codman Specialty Surgical, including neurosurgery and instruments, and Orthopedics and Tissue Technologies, including wound reconstruction, tissue technologies, orthopedic products and private-label offerings. The filing covers the three and nine months ended September 30, 2020, with comparisons to the corresponding 2019 periods. Results were materially affected by COVID-19-related reductions and deferrals of surgical procedures and hospital capital spending.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | 9M 2020 | 9M 2019 |
|---|---|---|---|---|
| Revenue | $370.2 million | $379.1 million | $983.2 million | $1,122.4 million |
| Gross margin | 63.6% | 62.4% | 62.0% | 63.0% |
| Operating income | $57.5 million | $(20.6) million | $98.7 million | $57.7 million |
| Operating margin | 15.5% | (5.4)% | 10.0% | 5.1% |
| Net income | $32.3 million | $(27.6) million | $41.1 million | $34.9 million |
| Diluted EPS | $0.38 | $(0.32) | $0.48 | $0.40 |
| Net cash from operating activities | Not separately provided for the quarter | Not separately provided for the quarter | $123.6 million | $142.2 million |
Q3 revenue declined 2.3% year over year but increased 43.1% sequentially from Q2 2020 as procedure volumes recovered. Nine-month revenue declined 12.4%. Q3 gross margin improved because of favorable mix and cost reductions; nine-month gross margin declined because of pandemic-related volume disruption. Net income and operating income benefited substantially from the absence of the $59.9 million in-process research and development charge recorded in Q3 2019 for the Rebound transaction.
- Q3 Codman Specialty Surgical revenue was $239.3 million, down 5.4% year over year; Orthopedics and Tissue Technologies revenue was $130.9 million, up 3.8%.
- Nine-month Codman Specialty Surgical revenue was $640.5 million, down 13.1%; Orthopedics and Tissue Technologies revenue was $342.7 million, down 11.1%.
- Cash and cash equivalents were $396.3 million at September 30, 2020, versus $198.9 million at December 31, 2019. Approximately $231.4 million was held by non-U.S. subsidiaries.
- Operating cash flow was $123.6 million, compared with $142.2 million in the prior-year period. Capital expenditures were $30.5 million, compared with $47.3 million.
- September 30 debt included $966.6 million under the senior credit facility, $92.3 million under the securitization facility and $575.0 million principal amount of convertible notes. Total debt principal was approximately $1.63 billion before considering discounts and issuance costs.
- Interest expense increased to $20.8 million in Q3 and $54.2 million for nine months, primarily because of the 2025 convertible notes and debt refinancing activity.
Material changes versus the prior comparable period
- COVID-19 reduced procedures, revenue and operating cash flow, although Q3 showed a significant recovery from Q2. International Q3 revenue declined 8%, while U.S. revenue was essentially flat.
- Operating expenses fell 30.8% in Q3 and 21.4% for nine months, reflecting cost reductions, lower selling costs and the absence of the prior-year Rebound IPR&D charge.
- Integra issued $575.0 million of 0.5% convertible senior notes due 2025, repaid $441.0 million of debt, purchased a $104.2 million note hedge and received $44.6 million from related warrant transactions.
- The company repurchased 2.1 million shares for $100.0 million during the first nine months. Approximately $125.0 million remained under the authorized repurchase program at September 30, 2020.
- On September 29, 2020, Integra agreed to sell its Extremity Orthopedics business to Smith & Nephew for approximately $240 million in cash. The business was classified as held for sale, with $160.0 million of assets and $12.3 million of liabilities classified separately on the balance sheet.
Guidance, outlook, risks and unusual items
- Management expected the full-year effective tax rate to be approximately 24.6%.
- Management stated that cash and available borrowings were sufficient to finance operations and capital expenditures for the foreseeable future and forecast compliance with debt covenants for the following twelve months.
- The July 2020 credit agreement amendment increased permitted consolidated total leverage ratios, including a maximum of 5.50-to-1.00 through June 30, 2021. The company was in compliance with its covenants at September 30, 2020.
- Management did not expect Q4 spending to reach the prior-year level and warned that renewed COVID-19 outbreaks could reduce procedures, delay customer payments, disrupt supply chains and impair liquidity or results. Further cost reductions could be required if the downturn were more severe or prolonged.
- The Extremity Orthopedics sale remained subject to regulatory approvals, employee consultation and other customary closing conditions and might be delayed or not completed.
- The FDA maintained its position that certain morselized amniotic membrane products may require regulation beyond Section 361 HCT/P requirements. Enforcement discretion was extended to May 31, 2021; related products represented less than 1% of nine-month consolidated revenue.
- A prior FDA Warning Letter concerning quality-system issues at the TEI Boston facility remained unresolved. The facility's products represented approximately 4.5% of nine-month consolidated revenue, although the warning letter did not restrict current manufacturing or shipments.
- Reported special charges totaled $22.6 million in Q3 and $60.7 million for nine months, including debt refinancing costs, convertible debt non-cash interest, structural optimization, regulatory, discontinued-product and COVID-19-related items.
Most important facts for investors to verify
- Whether COVID-19 procedure volumes and hospital capital spending continued to recover after September 30, 2020.
- Closing of the Extremity Orthopedics transaction, final cash proceeds, the $41.5 million payment to the Consortium of Focused Orthopedists and the effect on leverage and future revenue mix.
- Debt covenant compliance, refinancing needs and the maturity profile of the senior credit facility, securitization facility and 2025 convertible notes.
- Underlying profitability excluding special charges, cost reductions and the nonrecurring 2019 Rebound IPR&D expense.
- Resolution and potential commercial impact of the FDA matters involving morselized amniotic products and the TEI Boston facility.
- Cash conversion, inventory levels and the sustainability of liquidity as pandemic-related customer and supply-chain risks evolve.